Docking and Electronic Structure of Rutin, Myricetin, and Baicalein Targeting 3CLpro

Int J Mol Sci. 2023 Oct 12;24(20):15113. doi: 10.3390/ijms242015113.

Abstract

Understanding the role of 3CLpro protease for SARS-CoV-2 replication and knowing the potential of flavonoid molecules like rutin, myricetin, and baicalein against 3CLpro justify an investigation into their inhibition. This study investigates possible bonds and reactivity descriptors of rutin, myricetin, and baicalein through conformational and electronic properties. Density functional theory was used to determine possible interactions. Analyses were carried out through the molecular electrostatic potential, electron localization function, Fukui function descriptors based on frontier orbitals, and non-covalent interactions. A docking study was performed using a resolution of 1.55 Å for 3CLpro to analyze the interactions of rutin, myricetin, and baicalein. Scores of structures showed that rutin is the best ligand, followed by myricetin and baicalein. Docking studies showed that baicalein and rutin can establish effective interactions with residues of the catalytic dyad (Cys145 and His41), but just rutin forms a hydrogen bond. Myricetin, in turn, could not establish an effective interaction with Cys145. Baicalein interaction arose with active residues such as Arg188, Val186, Gln189, and Gln192. Interactions of rutin and myricetin with Arg188 and Gln189 were also found. A critical interaction was observed only for rutin with the hydroxyls of ring A with His41, and also for Cys145 with rings B and C, which is probably related to the highest score of rutin.

Keywords: 3CLpro protease; SARS-CoV-2; baicalein; density functional theory; docking; myricetin; rutin.

MeSH terms

  • Antiviral Agents / pharmacology
  • Flavanones*
  • Flavonoids / pharmacology
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Protease Inhibitors / chemistry
  • Rutin*

Substances

  • myricetin
  • Rutin
  • baicalein
  • Flavonoids
  • Flavanones
  • Protease Inhibitors
  • Antiviral Agents

Grants and funding

This research was funded by FAPDF, grant number 00193-00000869/2021-31.